Pfizer spells out PhIII talazoparib data in NEJM article; Tolero teams up with AbbVie for AML combo
→ David Hung offered a hard sell of his experimental PARP drug talazoparib while bidders lined up in what turned out as a $14 billion Medivation buyout by Pfizer. Now researchers are spelling out all the data in an article in the New England Journal of Medicine as Pfizer lines up a quick review and likely OK for a drug that will face some well entrenched competitors.
→ Salt Lake City-based Tolero Pharmaceuticals has struck a deal to share the costs on an upcoming combo cancer drug trial with AbbVie. Researchers will match Tolero’s alvocidib, a CDK9 drug, with AbbVie’s venetoclax for treatment resistant cases of acute myeloid leukemia.